Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Gehrig

Showing results (141-150 of 193) with videos related to

Pageof 20
Sort By:
American Journal of Obstetrics and Gynecology|May 2, 2016
The impact of surgical complications on health-related quality of life in women undergoing gynecologic and gynecologic oncology procedures: a prospective longitudinal cohort studyKemi M Doll, Emma L Barber, Jeannette T Bensen, et al.
Gynecologic Oncology|December 24, 2017
Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phaseArthur-Quan Tran, Daniel O Erim, Stephanie A Sullivan, et al.
Annals of Surgical Oncology|November 6, 2020
Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?David Pierce Mysona, Sharad Ghamande, Jin-Xiong She, et al.
Oncotarget|October 28, 2015
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancerJessica E Stine, Hui Guo, Xiugui Sheng, et al.
Gynecologic Oncology|December 7, 2002
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situJayanthi S Lea, Christine H Shin, Ellen E Sheets, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 12, 2014
Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancerRebecca Ann Previs, Joshua Kilgore, Renatta Craven, et al.
Obstetrics and Gynecology|November 10, 2015
Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian CancerEmma L Barber, John F Boggess, Linda Van Le, et al.
Gynecologic Oncology|January 8, 2017
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinomaStuart R Pierce, Jessica E Stine, Paola A Gehrig, et al.
Gynecologic Oncology|October 23, 2012
A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancerAngeles Alvarez Secord, Melissa A Geller, Gloria Broadwater, et al.
Human Pathology|October 20, 2004
PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomasB Wappenschmidt, E Wardelmann, A Gehrig, et al.
Pageof 20

Showing results (141-150 of 193) with videos related to

Sort By:
Pageof 20
American Journal of Obstetrics and Gynecology|May 2, 2016
The impact of surgical complications on health-related quality of life in women undergoing gynecologic and gynecologic oncology procedures: a prospective longitudinal cohort studyKemi M Doll, Emma L Barber, Jeannette T Bensen, et al.
Gynecologic Oncology|December 24, 2017
Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phaseArthur-Quan Tran, Daniel O Erim, Stephanie A Sullivan, et al.
Annals of Surgical Oncology|November 6, 2020
Are There Survival Differences Between Women with Equivalent Residual Disease After Interval Cytoreductive Surgery Compared with Primary Cytoreductive Surgery for Advanced Ovarian and Peritoneal Cancer?David Pierce Mysona, Sharad Ghamande, Jin-Xiong She, et al.
Oncotarget|October 28, 2015
The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancerJessica E Stine, Hui Guo, Xiugui Sheng, et al.
Gynecologic Oncology|December 7, 2002
Endocervical curettage at conization to predict residual cervical adenocarcinoma in situJayanthi S Lea, Christine H Shin, Ellen E Sheets, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 12, 2014
Obesity is associated with worse overall survival in women with low-grade papillary serous epithelial ovarian cancerRebecca Ann Previs, Joshua Kilgore, Renatta Craven, et al.
Obstetrics and Gynecology|November 10, 2015
Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian CancerEmma L Barber, John F Boggess, Linda Van Le, et al.
Gynecologic Oncology|January 8, 2017
Prior breast cancer and tamoxifen exposure does not influence outcomes in women with uterine papillary serous carcinomaStuart R Pierce, Jessica E Stine, Paola A Gehrig, et al.
Gynecologic Oncology|October 23, 2012
A multicenter evaluation of adjuvant therapy in women with optimally resected stage IIIC endometrial cancerAngeles Alvarez Secord, Melissa A Geller, Gloria Broadwater, et al.
Human Pathology|October 20, 2004
PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomasB Wappenschmidt, E Wardelmann, A Gehrig, et al.
Pageof 20